Kannalife Announces Completion of Name Change, Ticker Symbol Change
16 janv. 2019 09h00 HE
|
Kannalife, Inc.
DOYLESTOWN, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce that the Company’s name change...
Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions Corp.
01 août 2018 08h00 HE
|
Kannalife Sciences, Inc.
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange...
Kannalife Sciences to be Featured in Dateline NBC Segment Covering Company’s Research on CBD-Like Molecules as Treatments for HE, CTE
18 mai 2018 09h00 HE
|
Kannalife Sciences, Inc.
NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is excited to announce that the Company will be featured in a...
Kannalife Sciences CEO Dean Petkanas to Provide Presentation on Industry Advancement at 2018 Cannabinoids in Medicine Summit
27 avr. 2018 10h00 HE
|
Kannalife Sciences, Inc.
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a phyto-medical company, announced today that the Company’s CEO Dean Petkanas will be presenting at the 2018...
Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE
29 févr. 2016 09h00 HE
|
Kannalife, Inc.
NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the progress of its ongoing feasibility study being performed by...
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
16 févr. 2016 11h15 HE
|
Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
16 févr. 2016 11h15 HE
|
Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...
Kannalife Sciences, Inc. and Gridiron Cannabis Coalition, LLC Sign Binding Memorandum of Understanding
21 déc. 2015 09h00 HE
|
Kannalife, Inc.
NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc., a Phyto-Medical Company (“Kannalife”), announced the signing of a binding memorandum of understanding with Gridiron Cannabis...
KannaLife Sciences, Inc. Files PCT Patent Application for Novel Treatments for Neurodegenerative Disorders
23 janv. 2015 10h09 HE
|
Kannalife, Inc.
HUNTINGTON, N.Y., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. ("KannaLife") announces that it has filed a non-provisional patent application entitled: "Novel Functionalized 1,3-Benzene...
KannaLife Sciences, Inc. and Kannaway, LLC Sign Long Term Sales, Marketing and Product Development Agreement
31 mars 2014 09h30 HE
|
Kannalife, Inc.
WEST HILLS, N.Y., March 31, 2014 (GLOBE NEWSWIRE) -- KannaLife Sciences, Inc. ("KannaLife") and Kannaway LLC ("Kannaway"), have entered into a five year sales, marketing and product development...